Skip to main content
Clinical Trials/NCT01379001
NCT01379001
Completed
Not Applicable

Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI

Hebrew SeniorLife0 sites60 target enrollmentJuly 2008

Overview

Phase
Not Applicable
Intervention
Donepezil
Conditions
Cholinergic Function
Sponsor
Hebrew SeniorLife
Enrollment
60
Primary Endpoint
Cerebral blood flow
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

This research study will look at how medications affect the pattern of blood flow in the brain. This study will use a special type of MRI (magnetic resonance imaging) scan called perfusion MRI to make measurements of cerebral (brain) blood flow. The medications we will use in this study are scopolamine (commonly used to treat motion sickness), mecamylamine (used to treat high blood pressure), and donepezil (used to treat memory loss). Cognitive testing will also be obtained, and correlated with the blood flow patterns in the brain.

Detailed Description

Project Summary: This research project will investigate the value of combined pharmacologic manipulation and arterial spin-labeled perfusion MRI (pharmacologic ASL-pMRI) as an in vivo probe of cholinergic function. Methods to investigate cholinergic function in vivo are needed to better understand the role of acetylcholine in the physiology of the cerebral cortex, and in cognitive processes in health and in disease states. In this study, pharmacologic ASL-pMRI will be used to characterize the normal cerebral perfusion response to cholinergic manipulation in young healthy subjects. Cognitive measures will also be obtained and correlated with cerebral perfusion changes. Pharmacologic ASL-pMRI and cognitive testing will then be used to study how the cholinergic response is altered with normal aging and in delirium

Registry
clinicaltrials.gov
Start Date
July 2008
End Date
January 2013
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Hebrew SeniorLife
Responsible Party
Principal Investigator
Principal Investigator

Tamara Fong

Assistant Scientist/Assistant Professor of Neurology

Hebrew SeniorLife

Eligibility Criteria

Inclusion Criteria

  • healthy volunteers

Exclusion Criteria

  • Any neurological condition, such as brain tumor, history of stroke, seizure disorder, attention deficit disorder, normal pressure hydrocephalus, dementia, traumatic brain injury
  • Any major medical conditions, such a cancer, diabetes, glaucoma, prostate disease, uncontrolled hypertension
  • antihistamine use
  • tricyclic antidepressant use
  • presence of metal in body, including pacemaker, defibrillator, neurostimulator, metal implants, or foreign metal objects such as bullets or shrapnel.
  • anxiety or panic disorder
  • history of claustrophobia
  • pregnancy

Arms & Interventions

Older

Older healthy controls, aged 65-80

Intervention: Donepezil

Young

Young healthy controls, aged 21-35

Intervention: Scopolamine

Young

Young healthy controls, aged 21-35

Intervention: Placebo

Older

Older healthy controls, aged 65-80

Intervention: Scopolamine

Older

Older healthy controls, aged 65-80

Intervention: Placebo

Outcomes

Primary Outcomes

Cerebral blood flow

Time Frame: 3 hours

cerebral blood flow will be measured 3 hours after drug administration using Arterial spin-labeled perfusion MRI

Secondary Outcomes

  • cognitive performance(4 hours)

Similar Trials